Indonesia Pharma Outlook From IPMG Director Parulian Simanjuntak: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Indonesia is one of the least attractive pharma markets in Asia, with multinational companies facing major obstacles due to government restrictions and lack of transparency. Deficiencies in patent protection and a sizeable counterfeit industry make the situation even grimmer there. International Pharmaceutical Manufacturers' Group Executive Director Parulian Simanjuntak talked with PharmAsia News about the regulations that are putting a stranglehold on manufacturers in Indonesia and MNCs that might otherwise be thinking about entering Indonesia. IPMG, based in Jakarta, is the association for international pharmaceutical companies doing business in Indonesia.
You may also be interested in...
While the program is ambitious, government spending in Southeast Asia's largest market offers opportunities for expanding Chinese pharma companies.
HONG KONG - With an eye on developing a stronger regional pharmaceutical market, 10 countries in Southeast Asia are moving to eliminate trade barriers and improve drug safety by creating standard manufacturing and licensing processes
Mutual recognition agreement aims to eliminate some trade barriers between countries in the Association of Southeast Asian Nations and spur development of unified manufacturing and certification standards by 2011, with the goal of creating an EU-like alliance.